Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004945.
View in:
PubMed
subject areas
Acute Coronary Syndrome
Acute Coronary Syndrome
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Clinical Decision-Making
Clinical Decision-Making
Coronary Thrombosis
Coronary Thrombosis
Cost Savings
Cost Savings
Cost-Benefit Analysis
Cost-Benefit Analysis
Drug Costs
Drug Costs
Drug-Eluting Stents
Drug-Eluting Stents
Europe
Europe
Female
Female
Hemorrhage
Hemorrhage
Humans
Humans
Male
Male
Middle Aged
Middle Aged
Myocardial Ischemia
Myocardial Ischemia
Percutaneous Coronary Intervention
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors
Platelet Aggregation Inhibitors
Prasugrel Hydrochloride
Prasugrel Hydrochloride
Registries
Registries
Risk Assessment
Risk Assessment
Risk Factors
Risk Factors
Time Factors
Time Factors
Treatment Outcome
Treatment Outcome
United States
United States
authors with profiles
Usman Baber